June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Participant experience using novel perimetry tests to monitor glaucoma progression
Author Affiliations & Notes
  • Sandra Freeman
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Sofia De Arrigunaga
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Joyce Kang
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Yan Zhao
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Ana M. Roldan
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Michael M. Lin
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Tobias Elze
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Daniel Liebman
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Dolly Chang
    Genentech Inc, South San Francisco, California, United States
    Stanford University School of Medicine, Stanford, California, United States
  • David S Friedman
    Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Sandra Freeman None; Sofia De Arrigunaga None; Joyce Kang None; Yan Zhao None; Ana Roldan None; Michael Lin None; Tobias Elze Genentech Inc., Code F (Financial Support); Daniel Liebman None; Dolly Chang Genentech Inc., Code E (Employment); David Friedman Bausch and Lomb, W L Gore and Associates, Life Biosciences, Thea Pharmaceuticals, Code C (Consultant/Contractor), Genentech Inc., Zeiss Meditech, Code F (Financial Support)
  • Footnotes
    Support  Genentech, Inc. (San Fransisco, CA, USA)
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1262 – A0402. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sandra Freeman, Sofia De Arrigunaga, Joyce Kang, Yan Zhao, Ana M. Roldan, Michael M. Lin, Tobias Elze, Daniel Liebman, Dolly Chang, David S Friedman; Participant experience using novel perimetry tests to monitor glaucoma progression. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1262 – A0402.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Traditional office-based automated visual field (VF) testing requires expensive machines and poses logistical challenges that limit its use. Novel VF devices could change the paradigm of glaucoma monitoring and dramatically improve access to care if patients can reliably use these devices at home. A positive user experience is crucial for uptake and ongoing use of novel portable VF devices. We compare the patient experience using the IMOvifa virtual reality (VR) VF test (CREWT Medical Systems, Inc., Tokyo, Japan) and tablet-based Melbourne Rapid Fields (MRF) VF test (M&S Technologies, Niles, IL, USA) to that when using the Humphrey Field Analyzer (HFA).

Methods : As part of a pilot observational study, subjects who were either glaucoma suspects or had a prior glaucoma diagnosis performed VF tests on IMOvifa, MRF, and HFA in a random testing order. All subjects were reliable, experienced HFA testers. Participants were trained to use IMOvifa and MRF, then surveyed after completing their first test on each device. The survey used 5-point Likert questions to assess subjects’ experiences with the novel devices, how frequently they would be willing to use each one, and to compare each device to the HFA.

Results : We surveyed 56 research subjects with mean age of 62 years (range 30-79). A “very good” overall experience was reported by 75% and 96% of subjects for IMOvifa and MRF, respectively. 68% (95% CI = [56%, 80%]) and 66% (95% CI = [54%, 78%]) of subjects preferred IMOvifa and MRF over HFA, respectively (Table 1). Subjects primarily cited ease of use and comfort as reasons for their preference. Specifically, participants preferred the MRF’s portability and IMOvifa’s capability to allow both eyes to remain open during testing. 71% (95% CI = [60%, 83%]) and 79% (95% CI = [68%, 89%]) of subjects stated that they would be willing to take IMOvifa and MRF at least once per week, respectively (Table 2).

Conclusions : There was a strong preference for novel VR and tablet-based VF tests over HFA 24-2 SITA Standard, and overall participant experience using these devices was positive. Further research is needed to determine the role of these devices in clinical care.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Table 1: Subject preference comparing each novel device to HFA.

Table 1: Subject preference comparing each novel device to HFA.

 

Table 2: Frequency with which subjects would be willing to complete each novel device at home.

Table 2: Frequency with which subjects would be willing to complete each novel device at home.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×